NEW YORK (GenomeWeb) – Molecular diagnostics firm T2 Biosystems has filed for an initial public offering, seeking to raise as much as $69 million in proceeds.

The Lexington, Mass.-based firm plans to list its shares on the Nasdaq Global Market under ticker symbol "TTOO," it said in its Form S-1 filed with the US Securities and Exchange Commission on Tuesday. The underwriters on the offering are Goldman Sachs, Morgan Stanley, Leerink Partners, and Janney Montgomery Scott.

T2 Bio has not priced its shares or said how many shares it plans to offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.